Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

864
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
864
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

806
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
806
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

508
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
508
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

437
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
437
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

574
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
574

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression.

Brain, behavior, and immunity·2026
Same author

Baseline inflammatory profiles in moderate-to-severe depression and differential response to intermittent theta-burst stimulation.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

Electroconvulsive therapy in Germany: a nationwide multilevel analysis of determinants, regional patterns, and institutional variation.

European archives of psychiatry and clinical neuroscience·2026
Same author

Re-evaluating response rates, time to reorientation and inadequate seizure duration in magnetic seizure therapy for schizophrenia and major depression.

Molecular psychiatry·2026
Same author

Comment on Residual neuromuscular blockade following electroconvulsive therapy.

Anaesthesia and intensive care·2026
Same author

Relapse Prevention After Successful ECT for Depression: The Role of Lithium and Continuation/Maintenance ECT.

The American journal of psychiatry·2026

Related Experiment Videos

Ketamine versus ECT for major depression: flawed evidence base

Richard Braithwaite1, Ana Jelovac2, Charles H Kellner3

  • 1Sussex Partnership NHS Foundation Trust, Meadowfield Hospital, Worthing, West Sussex, UK; Committee on Electroconvulsive Therapy and Related Treatments, Royal College of Psychiatrists, London, UK.

The Lancet. Psychiatry
|October 25, 2025
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos